Ascentage Pharma Group In... (AAPG)
19.68
0.31 (1.60%)
At close: Feb 20, 2025, 3:59 PM
19.67
-0.03%
After-hours: Feb 20, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 18.8 |
| Market Cap | 1.70B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.17 |
| PE Ratio (ttm) | -115.74 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 19.9 |
| Volume | 49,651 |
| Avg. Volume (20D) | 273,688 |
| Open | 19.39 |
| Previous Close | 19.37 |
| Day's Range | 19.50 - 19.83 |
| 52-Week Range | 16.50 - 19.86 |
| Beta | undefined |
About AAPG
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; A...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 24, 2025
Employees 574
Stock Exchange NASDAQ
Ticker Symbol AAPG
Website https://www.ascentage.cn